Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.33 |
| ▸ | CCNK | O75909 | 3/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.33 |
| ▸ | CDK2 | P24941 | 3/20 | 0.33 |
| ▸ | CDK9 | P50750 | 3/20 | 0.33 |
| ▸ | CDK12 | Q9NYV4 | 3/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | SOS1 | Q07889 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23770787 | 0.87 | PDE10A (0.35) | CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL23770621 | 0.86 | PDE10A (0.35) | CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL23770649 | 0.82 | PIM1 (0.34) | CYP1A2 | |
| SCHEMBL23770643 | 0.80 | ADRB2 (0.37) | CYP1A2CYP2C9ADRB2CYP2C19SOS1 | |
| SCHEMBL23770598 | 0.80 | ADRB2 (0.43) | CYP1A2CYP2C9ADRB2CYP2C19 | |
| SCHEMBL23770766 | 0.80 | PRKCQ (0.35) | CYP1A2CYP2C9 | |
| SCHEMBL23770416 | 0.80 | PTPN11 (0.37) | — | |
| SCHEMBL23770413 | 0.78 | CCNT1 (0.47) | CCNT1CCNKCCNE1CDK2CDK9 | |
| SCHEMBL23770712 | 0.78 | NPC1 (0.33) | CYP1A2CYP2C19 | |
| SCHEMBL23770480 | 0.77 | GRIN2B (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3504194-B1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2021-08-18 | — | — | EP | disclosed |